Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 4, 2010, Pages 203-212

  Johnson, Todd J ^a   Gupta, Kavita M ^a   Fabian, Judit ^a   Albright, Theodore H ^a   Kiser, Patrick F ^a,b  

^a Department of Electrical and Computer Engineering   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Anti HIV drug; Controlled release; Dual delivery; Intravaginal ring; Microbicide; Polyurethane

Indexed keywords

DAPIVIRINE; ETHINYLESTRADIOL PLUS ETONOGESTREL; POLYURETHAN; TENOFOVIR;

ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; HYDROPHILICITY; IN VITRO STUDY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RADIATION SCATTERING; SUSTAINED DRUG RELEASE; THERMOSTABILITY; VAGINA RING; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; COMPRESSIVE STRENGTH; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; PHOSPHONIC ACIDS; POLYURETHANES; PYRIMIDINES;

EID: 75149116238     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.11.007     Document Type: Article

References (52)

1. Barnhart K.T., Timbers K., Pretorius E.S., Lin K., and Shaunik A. In vivo assessment of NuvaRing placement. Contraception 72 (2005) 196-199
2. Baronsky J., Bongaerts S., Traeubel M., Weiss H.C., and Urbanetz N. The study of different solid forms of Emodepside. Eur. J. Pharm. Biopharm. 71 (2009) 88-99
3. Bounds W., Szarewski A., Lowe D., and Guillebaud J. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur. J. Obstet. Gynecol. Reprod. Biol. 48 (1993) 123-125
4. Buckheit Jr. R.W., Watson K.M., Morrow K.M., and Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antivir. Res. (2009)
5. Coplan P.M., Mitchnick M., and Rosenberg Z.F. Public health. Regulatory challenges in microbicide development. Science 304 (2004) 1911-1912
6. Cranage M., Sharpe S., Herrera C., Cope A., Dennis M., Berry N., Ham C., Heeney J., Rezk N., Kashuba A., Anton P., Mcgowan I., and Shattock R. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5 (2008) e157 (discussion e157)
7. Crowley M.M., Zhang F., Repka M.A., Thumma S., Upadhye S.B., Battu S.K., Mcginity J.W., and Martin C. Pharmaceutical applications of hot-melt extrusion. Part I. Drug Dev. Ind. Pharm. 33 (2007) 909-926
8. Das K., Clark Jr. A.D., Lewi P.J., Heeres J., De Jonge M.R., Koymans L.M., Vinkers H.M., Daeyaert F., Ludovici D.W., Kukla M.J., De Corte B., Kavash R.W., Ho C.Y., Ye H., Lichtenstein M.A., Andries K., Pauwels R., De Bethune M.P., Boyer P.L., Clark P., Hughes S.H., Janssen P.A., and Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47 (2004) 2550-2560
9. Di Fabio S., Van Roey J., Giannini G., Van Den Mooter G., Spada M., Binelli A., Pirillo M.F., Germinario E., Belardelli F., De Bethune M.P., and Vella S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17 (2003) 1597-1604
10. Dieben T.O., Roumen F.J., and Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet. Gynecol. 100 (2002) 585-593
11. Faheem A., McCoy C., McBride M., Malcolm K., Woolfson D., and Sparks M. Simultaneous sustained release of maraviroc and dapivirine from silicone elastomer vaginal rings. 16th CROI Conference (2009) (abstract 1069)
12. Fletcher P., Harman S., Azijn H., Armanasco N., Manlow P., Perumal D., De Bethune M.P., Nuttall J., Romano J., and Shattock R. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 53 (2009) 487-495
13. Furst W., and Hallstrom S. Simultaneous determination of myocardial nucleotides, nucleosides, purine bases and creatine phosphate by ion-pair high-performance liquid chromatography. J. Chromatogr. 578 (1992) 39-44
14. Grant R.M., Hamer D., Hope T., Johnston R., Lange J., Lederman M.M., Lieberman J., Miller C.J., Moore J.P., Mosier D.E., Richman D.D., Schooley R.T., Springer M.S., Veazey R.S., and Wainberg M.A. Whither or wither microbicides?. Science 321 (2008) 532-534
15. Gupta K.M., Pearce S.M., Poursaid A.E., Aliyar H.A., Tresco P.A., Mitchnik M.A., and Kiser P.F. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 97 (2008) 4228-4239
16. Gupta P., Collins K.B., Ratner D., Watkins S., Naus G.J., Landers D.V., and Patterson B.K. Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J. Virol. 76 (2002) 9868-9876
17. Hardy E., Hebling E.M., Sousa M.H., Almeida A.F., and Amaral E. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 76 (2007) 126-131
18. Herrera C., Cranage M., Mcgowan I., Anton P., and Shattock R.J. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob. Agents Chemother. 53 (2009) 1797-1807
19. Hladik F., and Hope T.J. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6 (2009) 20-28
20. In: Huynh-Ba K. (Ed). Handbook of Stability Testing in Pharmaceutical Development (2009), Springer, New York
21. Klasse P.J., Shattock R., and Moore J.P. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59 (2008) 455-471
22. Klasse P.J., Shattock R.J., and Moore J.P. Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS Med. 3 (2006) e351
23. Koetsawang S., Ji G., Krishna U., Cuadros A., Dhall G.I., Wyss R., Rodriquez La Puenta J., Andrade A.T., Khan T., Kononova E.S., et al. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Contraception 41 (1990) 143-150
24. Malcolm R.K., Woolfson A.D., Toner C.F., Morrow R.J., and Mccullagh S.D. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J. Antimicrob. Chemother. 56 (2005) 954-956
25. Mayer K.H., Maslankowski L.A., Gai F., El-Sadr W.M., Justman J., Kwiecien A., Masse B., Eshleman S.H., Hendrix C., Morrow K., Rooney J.F., and Soto-Torres L. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20 (2006) 543-551
26. Microbicideupdate. Pipeline Update of Microbicide and PrEP Candidates (2009), Alliance For Microbicide Development
27. Ndesendo V.M., Pillay V., Choonara Y.E., Buchmann E., Bayever D.N., and Meyer L.C. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS Pharm. Sci. Technol. 9 (2008) 505-520
28. Nel A., Smythe S., Young K., Malcolm K., Mccoy C., Rosenberg Z., and Romano J. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 51 (2009) 416-423
29. Newman A.W., and Byrn S.R. Solid-state analysis of the active pharmaceutical ingredient in drug products. Drug Discov. Today 8 (2003) 898-905
30. Novak A., De La Loge C., Abetz L., and Van Der Meulen E.A. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 67 (2003) 187-194
31. Nuttall J.P., Thake D.C., Lewis M.G., Ferkany J.W., Romano J.W., and Mitchnick M.A. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob. Agents Chemother. 52 (2008) 909-914
32. Romano J., Variano B., Coplan P., Van Roey J., Douville K., Rosenberg Z., Temmerman M., Verstraelen H., Van Bortel L., Weyers S., and Mitchnick M. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25 (2009) 483-488
33. Rosen R.K., Morrow K.M., Carballo-Dieguez A., Mantell J.E., Hoffman S., Gai F., Maslankowski L., El-Sadr W.M., and Mayer K.H. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J. Womens Health (Larchmt) 17 (2008) 383-392
34. Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur. J. Contracept. Reprod. Health Care 7 Suppl. 2 (2002) 19-24 discussion 37-9
35. Sarkar N.N. The combined contraceptive vaginal device (NuvaRing): a comprehensive review. Eur. J. Contracept. Reprod. Health Care 10 (2005) 73-78
36. Saxena B.B., Han Y.A., Fu D., Rathnam P., Singh M., Laurence J., and Lerner S. Sustained release of microbicides by newly engineered vaginal rings. AIDS 23 (2009) 917-922
37. Schader S.M., Schachter J., Oliveira M., Invernizzi C., and Wainberg M.A. Evaluation of different in vitro models to predict candidate HIV microbicide compound combination synergy. 14th CROI Conference (2007)
38. Siepmann J., and Peppas N.A. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 48 (2001) 139-157
39. Skoler-Karpoff S., Ramjee G., Ahmed K., Altini L., Plagianos M.G., Friedland B., Govender S., De Kock A., Cassim N., Palanee T., Dozier G., Maguire R., and Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1977-1987
40. Srinivas R.V., and Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42 (1998) 1484-1487
41. Terrazas-Aranda K., Van Herrewege Y., Hazuda D., Lewi P., Costi R., Di Santo R., Cara A., and Vanham G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob. Agents Chemother. 52 (2008) 2544-2554
42. Trapp S., Turville S.G., and Robbiani M. Slamming the door on unwanted guests: why preemptive strikes at the mucosa may be the best strategy against HIV. J. Leukoc. Biol. 80 (2006) 1076-1083
43. Tremblay C. Effects of HIV-1 entry inhibitors in combination. Curr. Pharm. Des. 10 (2004) 1861-1865
44. Turpin J.A. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11 (2002) 1077-1097
45. Unaids, 2008. Report on the global AIDS epidemic.
46. Van Herrewege Y., Vanham G., Michiels J., Fransen K., Kestens L., Andries K., Janssen P., and Lewi P. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother. 48 (2004) 3684-3689
47. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., Marx P.A., Dufour J., Colonno R.J., Shattock R.J., Springer M.S., and Moore J.P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 (2005) 99-102
48. Weisberg E., Fraser I.S., Baker J., Archer D., Landgren B.M., Killick S., Soutter P., Krause T., and D'arcangues C. A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. Contraception 62 (2000) 83-89
49. Wilson D.P., Coplan P.M., Wainberg M.A., and Blower S.M. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 9835-9840
50. Woolfson A.D., Elliott G.R., Gilligan C.A., and Passmore C.M. Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester. J. Control. Release 61 (1999) 319-328
51. Woolfson A.D., Malcolm R.K., and Gallagher R. Drug delivery by the intravaginal route. Crit. Rev. Ther. Drug Carrier Syst. 17 (2000) 509-555
52. Woolfson A.D., Malcolm R.K., Morrow R.J., Toner C.F., and Mccullagh S.D. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 325 (2006) 82-89